Business
Sernova Highlights Positive Results Presented at the American Diabetes Association's Virtual 80th Scientific Sessions
(via TheNewswire) LONDON, ONTARIO - TheNewswire - June 18, 2020 - Sern...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova Highlights Positive Results Presented at the American Diabetes Association's Virtual 80th Scientific Sessions(via TheNewswire)\n \n \nLONDON, ONTARIO - TheNewswire - June 18, 2020 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine therapeutics company, highlights positive results from its submitted abstract entitled \"Clinical Validation of the Implanted Pre-Vascularized Cell Pouch(TM) as a Viable, Safe Site for Diabetes Cell Therapy,\" selected for presentation at the American Diabetes Association's (ADA) 80th Scientific Sessions held virtually June 12-16, 2020.\n\n\n \n\"Sernova was honored that its abstract was selected under peer review to be presented at the prestigious ADA Scientific Sessions. The findings reported in diabetic patients, demonstrate that human donor islets transplanted into Sernova's Cell Pouch consistently demonstrate islet survival and the ability to produce the array of hormones required to treat diabetes,\" said Dr. Philip Toleikis, President and CEO of Sernova. \n\n\n \nThe following provides the background of our scientific presentation: \n\n\n \n\n\n- Cellular transplantation therapy has the potential to treat severe, chronic diseases such as Type 1 Diabetes (T1D). The transplantation site and device approach are major factors influencing successful clinical outcomes; \n\n\n\n- With new cell-based emerging technologies, there continues to be a need to find a safe, retrievable, biologically compatible device for cellular transplantation and we believe Sernova's Cell Pouch System may provide such a solution; \n\n\n\n- The transplantation of insulin-producing islets is a cellular replacement therapy for severe T1D in patients who experience life-threatening severe hypoglycemia unawareness events; \n\n\n\n- In this clinical indication, Sernova has conducted a physician sponsored first-in-human study in Canada and currently has an ongoing company-sponsored Phase I/II human clinical study at the University of Chicago. In both clinical studies, patients with T1D were implanted with both sentinel (small devices removed to assess cell survival) and larger therapeutic devices, anywhere between 1 to 6 months;\n\n\n\n- After being placed on immunosuppression, islets were isolated from donor pancreata and transplanted into patients within the device chambers. When pos...